Why Keryx Biopharmaceuticals (KERX) Stock Is Down Today

NEW YORK (TheStreet) -- Keryx Biopharmaceuticals (KERX) shares are plummeting, down -13.5% to $12.30, on Thursday after the company posted a net loss more than 10 cents per share worse than it reported last year.

The biotech company posted a net loss of $13.5 million, or -15 cents per share, missing analysts estimates by 7 cents. The company reported a net loss of -2 cents and $2.1 million during the same period last year.

Must Read: Warren Buffett's 10 Favorite Growth Stocks 

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

KERX Chart

KERX data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

More from Markets

Stocks Search for Direction as Trump Comments Lead to Worries Over China Talks

Stocks Search for Direction as Trump Comments Lead to Worries Over China Talks

Owner of Moviepass Sees Stock Plummet

Owner of Moviepass Sees Stock Plummet

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

General Electric's Stock Gets Routed as CEO Flannery Flubs Presentation

General Electric's Stock Gets Routed as CEO Flannery Flubs Presentation

Italy's President Gives Mandate For Anti-European Government in Rome

Italy's President Gives Mandate For Anti-European Government in Rome